Trending...
- California: Governor Newsom announces appointments 9.10.25 - 339
- John Thomas calls for unity and prayer after tragic loss - 310
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 302
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
- Descryber Launches Innovative Web App to Simplify DIY Trademark Applications
- LVN Jobs in LA Connects Licensed Vocational Nurses with Top LVN Staffing Jobs in Los Angeles
- California-based productions win big at Emmy Awards
- White Glove Restoration Expands 24/7 Emergency Response Team Across San Diego County
- Marin's Rising Star Easton Cain Revives American Regionalism in the Bay Area
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
- City of Long Beach Launches Redesigned Jobs Webpage
- Cabrillo Economic Development Corporation Celebrates Completion of Dolores Huerta Gardens
- Lightning Motorcycle's Next-Gen Prototype Hits 174 MPH on Its Lowest Performance Setting
- Long Beach Health Department Launches Early Childhood Mental Health Program to Support Families and Childcare Providers
- Dane Flanigan joins Raymond James in Pasadena as Financial Advisor
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Pacsun Announces Industry First Pacsun Youth Advisory Council: Empowering Its Consumers as Co-Creators in Brand Strategy
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
- NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
- America's SBDC Announces 2025-2026 Board of Directors
- Avoid Swirl Marks When You Get a Car Wash in Downey CA
- Freedom Flourishes in Dutch Capital on Destination: Scientology, Amsterdam
- Poncho Tha Popstar: The West's Next King
- Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
- Celebrity Chef Nicole Andrea Guzman Releases Her First Childrens Book
- Thorn Ridge® Creates a World of Legends & Lore
- Screenwriting Cruise Adds Howard Suber, Ph.D., to Inaugural 7-Day Screenwriting Lab at Sea
- Twice the Laughs: Comedy Star Don Barnhart Rotates Residency at Both Delirious Comedy Club Locations in Las Vegas
- Voices for Humanity Ignites a Revolution for Learning with Eva Rehorova
- Omnigarde AI-Powered Face Recognition Achieves Top Global Rankings in Prestigious NIST Evaluation
- Petitioner Urges White House to Issue Executive Order on Divorce Fairness
- Car Wash Deal in Downey CA Prices Starting from $8
- Dr. Vincent Malfitano Elected to Central Council of The Italian Catholic Federation, National Gov